|Bid||57.05 x 800|
|Ask||57.12 x 800|
|Day's Range||56.80 - 59.02|
|52 Week Range||44.27 - 77.63|
|Beta (3Y Monthly)||1.70|
|PE Ratio (TTM)||35.54|
|Earnings Date||Aug 5, 2019 - Aug 9, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||71.40|
Quidel Corporation (QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that Quidel has received 510(k) clearance from the Unites States Food and Drug Administration (FDA) to market the Quidel Triage® TOX Drug Screen, 94600, a fluorescence immunoassay for the qualitative determination of the presence of drug and/or metabolites in human urine of up to 9 drug assays. The test is to be used with Quidel’s Triage® MeterPro instrumented system.
Masimo (MASI) gets FDA nod for its O3 Regional Oximetry that will help in delivering accurate measurement with respect to neonatal patients.
As we already know from media reports and hedge fund investor letters, many hedge funds lost money in fourth quarter, blaming macroeconomic conditions and unpredictable events that hit several sectors, with technology among them. Nevertheless, most investors decided to stick to their bullish theses and recouped their losses by the end of the first quarter. […]
Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.
HMS Holdings (HMSY) is gaining traction from the growing PI and TPM analytical services. However, stiff competition remains a concern.
A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with price performance.
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
Medical technology stocks hit record highs last year and are rising thus far in 2019. Two of the fastest growing among them have tacked on double-digit earnings growth for several years.
DexCom (DXCM) is gaining traction from lucrative glucose monitoring market, solid international market presence and strong product portfolio.
Quidel Corporation (QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it has entered into separate, privately negotiated exchange agreements with certain holders of its 3.25% Convertible Senior Notes due 2020 (the “2020 Notes”). Pursuant to these exchange agreements Quidel will exchange approximately $45.372 million in aggregate principal amount of the 2020 Notes for (i) approximately 1,273,601 shares of the company’s common stock plus (ii) an additional number of newly issued shares of the company’s common stock to be determined based on the volume weighted average price of the company’s common stock over the three consecutive trading days commencing on June 5, 2019.
Medidata Solutions (MDSO) continues to benefit from solid R&D focus, Rave Genomics platform and cloud-based services. However, stiff competition remains a concern.
Today, we'll introduce the concept of the P/E ratio for those who are learning about investing. To keep it practical...
Quidel Corporation (QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today that it will present at the William Blair 39th Annual Growth Stock Conference at the Loews Chicago hotel in Chicago, Illinois on Thursday, June 6, 2019. Randy Steward, chief financial officer, will present on Thursday, June 6, 2019 at 1:20 p.m. Central Time (11:20 a.m. Pacific Time) with a question-and-answer session scheduled immediately following the presentation. Participants should allow approximately five to ten minutes prior to the presentation's start time to visit the site and download any streaming media software needed to listen to the Internet webcast.
Masimo (MASI) receives FDA 510 (k) clearance for Radius PPG, which is set to become an important breakthrough in patient monitoring.
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex volatility remains a concern.
DaVita (DVA) is gaining steadily from expansion in international markets, strong demand in dialysis services and prudent acquisitions. However, divestment of DMG segment might lower cash flows.